跳至主要內容
MediHelp
MediHelp 藥品參考

藥品參考

Olaparib

Olaparib is a medicine in the class oncology. It is used for breast cancer.

最後更新 來源: US FDA label

僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。

本頁的臨床內容僅提供英文版。

重點資訊

藥物類別
Oncology
ATC 代碼
L01XK01
常見劑型
錠劑
已知交互作用
102 (嚴重: 37 · 中度: 60 · 輕微: 5)
商品名
3
國家與市場
3

劑型、規格與商品名稱會因國家而異。請核對您手上的產品。

用途

作用方式

Olaparib inhibits PARP enzymes (PARP1, PARP2, PARP3). Cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, causing DNA damage and cancer cell death, with greater activity in cells deficient in BRCA1/2, ATM or other HRR genes.

成人常用劑量（仿單摘要）

All indications: 300 mg orally twice daily, with or without food; swallow tablets whole, do not chew, crush, dissolve or divide

僅摘錄仿單中第一行劑量說明；完整的劑量內容請見 App。

懷孕與哺乳

懷孕
Unsafe No human data. Based on its mechanism (PARP inhibition) and rat studies showing malformations and embryo loss below human exposure, it can cause fetal harm. Avoid; confirm a negative pregnancy test, and use effective contraception during treatment and for 6 months after (EU: two methods).
哺乳
Unsafe No data on milk levels or infant effects. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 1 month after the last dose (US label); the EU label contraindicates breastfeeding.

已通報的副作用

  • Nausea
  • Fatigue
  • Anemia
  • Vomiting
  • Diarrhea
  • Decreased appetite

哪些人需要特別留意

  • MDS/AML occurred in about 1.2% of patients, many fatal; monitor CBC at baseline and monthly; discontinue if confirmed.
  • Pneumonitis occurred in 1.0%, including fatal cases; interrupt if suspected, discontinue if confirmed.
  • Venous thromboembolism including fatal PE; VTE occurred in 8% of mCRPC patients; monitor and treat.

請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏，以及您正在使用的所有其他藥物或保健品。

重要交互作用 (102)

All 102 interactions, with severity and what to do

Pro+ 會員專屬

解鎖完整頁面

建立帳號並開始 Pro+ 試用，即可開啟 Olaparib 的完整藥品專論：劑量、懷孕與哺乳、副作用、警示及所有交互作用。

  • Dosing by age, kidney and liver function, and further dose lines
  • Renal and hepatic dose adjustments
  • How to give it
  • Pharmacokinetics
  • Patient counselling points
  • Food interactions
建立免費帳號 登入

在網頁版免費試用 Pro+ 14 天，無需信用卡。

同類別的其他藥品

常見問題

What is Olaparib used for?

Olaparib is a medicine in the class oncology. It is used for Breast cancer, Ovarian cancer, Pancreatic cancer, Prostate cancer.

What side effects have been reported with Olaparib?

Nausea, Fatigue, Anemia, Vomiting, Diarrhea, Decreased appetite.

Can Olaparib be taken in pregnancy or while breastfeeding?

Pregnancy: Unsafe. No human data. Based on its mechanism (PARP inhibition) and rat studies showing malformations and embryo loss below human exposure, it can cause fetal harm. Avoid; confirm a negative pregnancy test, and use effective contraception during treatment and for 6 months after (EU: two methods). Breastfeeding: Unsafe. No data on milk levels or infant effects. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 1 month after the last dose (US label); the EU label contraindicates breastfeeding.

What does Olaparib interact with?

MediHelp lists 102 known interactions for Olaparib. Major: 37 · Moderate: 60 · Minor: 5. The most serious include Amiodarone, Amobarbital, Apalutamide.

在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查

在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。

下載於App Store 立即下載Google Play

依 A–Z 瀏覽 · 藥品參考

取得 App 登入